AgingResearch.NewsJoin free

Appello Pharmaceuticals

CompanyUnited States

Appello Pharmaceuticals develops one asset, in phase 2 (AP-472 in Parkinson's disease). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • AP-472

    Adjunctive therapy to levodopa for motor fluctuations in Parkinson's disease.

    Phase 2, Small molecule, Parkinson's disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1
  • Similar companies6

Intelligence